IGC Pharma Unveils Research on IGC-1C Targeting Tau Protein in Alzheimer's

IGC Pharma, Inc. (NYSE American: IGC) has revealed promising preclinical data suggesting the therapeutic potential of IGC-1C, a novel small-molecule modulator. Research indicates that IGC-1C effectively targets tau protein phase separation, paving the way for new approaches to treat neurodegenerative diseases.

The company had previously announced that both IGC-1C and IGC-1A have been identified by their Artificial Intelligence (AI) model as potential GLP-1 receptor agonists. This positions them as promising candidates for weight loss treatments and offers a unique strategy to combat Alzheimer's disease.

Preclinical studies demonstrate that IGC-1C shows a dissociation constant (Kd) of 3.95 ± 0.32 μM with tau, indicating a strong binding affinity that underscores its potential as a therapeutic agent. The Kd value is significant as it measures the interaction strength between IGC-1C and tau, reinforcing IGC-1C's efficacy in modulating tau protein, which is involved in neurofibrillary tangle formation, a hallmark of Alzheimer's disease.

IGC-1C, a cyclic dipeptide-based small-molecule modulator, introduces a novel method to address tau-related pathology. In-vitro studies reveal that IGC-1C inhibits tau condensates formed by zinc-induced liquid-liquid phase separation (LLPS) and prevents their transformation into toxic fibrils. By disrupting this phase separation and aggregation process, IGC-1C has the potential, pending further trials, to halt tau tangle formation, presenting a promising breakthrough in slowing Alzheimer's progression.

"The discovery of IGC-1C's dual action, targeting both tau and GLP-1 receptors, marks a significant advancement in our Alzheimer's disease research and treatment," stated Ram Mukunda, CEO of IGC Pharma. "This innovative approach aligns with our strategy to develop and leverage assets in the metabolic disease space, aiming to enhance treatment outcomes for Alzheimer's, metabolic disorders, and obesity. By addressing tau tangles and incorporating GLP-1 receptor modulation, IGC-1C is positioned at the forefront of developing transformative therapies. We are dedicated to advancing our molecules through future clinical trials to fully realize their potential and provide substantial value for our shareholders."

Tau pathology in Alzheimer's is driven by the hyperphosphorylation of tau proteins, leading to neurotoxic tangle formation that correlates strongly with cognitive decline, memory loss, and other debilitating symptoms. Neurofibrillary tangles typically emerge in the later stages of Alzheimer's and serve as a vital indicator of disease progression.

Moreover, IGC-1C has also been identified as a potential GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone with receptors throughout the brain, including regions affected by Alzheimer's. Research suggests that GLP-1 is neuroprotective against Aβ toxicity by reducing oxidative stress and inflammation, enhancing Aβ clearance, improving insulin signaling, and promoting neurogenesis. This dual mechanism positions IGC-1C as a promising candidate for treating weight loss and neurodegenerative and metabolic disorders, although further validation is needed.

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on innovative treatments for Alzheimer's disease. Their portfolio includes the TGR family, such as TGR-63, targeting amyloid plaques, a hallmark of Alzheimer's. Their IGC-C and IGC-M platforms are advancing in preclinical studies, concentrating on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Their lead candidate, IGC-AD1, a cannabinoid-based treatment, is currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's. Interim data for IGC-AD1 indicates faster-acting, more effective relief compared to traditional medications. Additionally, their AI models predict potential biomarkers for early Alzheimer's detection, optimize clinical trials, and predict receptor affinity. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.